Marta Garcia (PhD)
About Marta Garcia (PhD)
Marta Garcia (PhD) is a Senior Global Trial Manager in Early Development at Bristol Myers Squibb and Celgene Institute for Translational Research Europe, and serves as CEO and COO at RPO Clinical and RPO Scientific in Spain.
Company
Marta Garcia currently serves as the Chief Executive Officer and Co-Owner at RPO Clinical in Spain. Additionally, she holds the position of Chief Operating Officer at RPO Scientific. In these roles, she oversees various operational and strategic aspects of the companies, guiding their direction and growth.
Title
Marta Garcia holds the title of Senior Global Trial Manager, Early Development at Bristol Myers Squibb and also serves as a Senior Global Study Manager, Early Development at the Celgene Institute for Translational Research Europe (CITRE) in Spain. Her responsibilities include the oversight of early-phase clinical trials and the management of study teams.
Background
Marta Garcia has extensive experience in global trial management, having worked with numerous companies over the years. She has held significant positions at Covance, PPD, Syreon, MG Clinical Ltd., INC Research, Kendle International, and PAREXEL, contributing to various clinical trials in numerous therapeutic areas. Her roles have ranged from Clinical Research Associate to Global Project Manager, highlighting her expertise across different facets of clinical research.
Education and Expertise
Marta Garcia earned a PhD in Molecular Oncology from the University of Nottingham and holds a BSc (Hons) in Medical Microbiology from the University of Leeds. She also achieved a Certificate in Advanced English from the University of Cambridge. Her academic background provided a strong foundation for her career in clinical research, where she has specialized in early development trials and has therapeutic experience in multiple areas including Oncology, Hematology, and Infectious Diseases, among others.
Achievements
Throughout her career, Marta Garcia has successfully managed full-service global registration studies involving over 25 countries across several continents. She has significant experience in early development, including First-In-Human Phase I trials in various therapeutic areas. Additionally, she has been involved in the development of radiopharmaceuticals and has held full operational and financial responsibilities for numerous projects. Her expertise also includes managing clinical trials for various medical devices and setting up independent teams for CROs without EU representation.